Visual Erotica, EMG, and Sexual Psychophysiological Arousal (VESPA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of British Columbia
ClinicalTrials.gov Identifier:
NCT01700361
First received: August 27, 2012
Last updated: June 3, 2013
Last verified: June 2013
  Purpose

This study will examine whether measurement of pelvic floor muscle sEMG activity is responsive to explicit sexual stimuli, and whether it correlates with self-reports of sexual arousal in healthy women. Participants' vaginal, labial and anal sEMG readings will be monitored during exposure to neutral, erotic and anxiety-provoking films. Participants will also be required to provide subjective ratings of sexual arousal before and after each film. If pelvic floor sEMG is validated as a psychophysiological measure, these findings may have important clinical and research implications by providing a greater understanding of the mechanisms involved in sexual arousal and for providing a relatively easy method of assessing sexual arousal in a clinical or research setting.


Condition
Sexual Arousal

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: Visual Erotica, EMG, and Sexual Psychophysiological Arousal (VESPA)

Further study details as provided by University of British Columbia:

Primary Outcome Measures:
  • Pelvic floor muscle sEMG activity [ Time Frame: This study involves 1 testing session approximately 20 minutes in duration ] [ Designated as safety issue: No ]
    Changes in pelvic floor muscle activity in responsive to exposure to explicit sexual stimuli will be assessed using pelvic floor surface electromyography (sEMG).


Secondary Outcome Measures:
  • Sexual Arousal [ Time Frame: This study involves 1 testing session approximately 20 minutes in duration ] [ Designated as safety issue: No ]
    Self-report sexual arousal will be measured with the Sexual Arousability Inventory (SAI ; Hoon, Hoon, & Wincze, 1976)

  • Sexual Function [ Time Frame: This study involves 1 testing session approximately 20 minutes in duration ] [ Designated as safety issue: No ]
    Self-reported sexual function will be measured using the Female Sexual Function Inventory (FSFI; Rosen et al., 2000) and the Derogatis Sexual Functioning Inventory (DSFI; Derogatis & Melisaratos, 1979).


Enrollment: 15
Study Start Date: October 2012
Study Completion Date: February 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
No treatment
This is an observational study. Women in this study are not receiving any treatments.

Detailed Description:

HYPOTHESES:

  1. Investigators hypothesize that, relative to the neutral films, PFM EMG activity will significantly increase in response to the erotic film as measured by the labial, anal, and vaginal EMG probes.
  2. Investigators hypothesize that, relative to the anxiety-provoking film, PFM EMG activity will significantly increase in response to the erotic film as measured by the labial, anal, and vaginal EMG probes.
  3. Investigators hypothesize that continuously measured subjective sexual arousal (via the arousometer) will correlate significantly with PFM EMG activity during the erotic film.
  Eligibility

Ages Eligible for Study:   19 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Healthy females.

Criteria

Inclusion Criteria:

  • Must be female, between the ages of 19-45
  • Must be premenopausal
  • Must be previously sexually active
  • Must be fluent in English

Exclusion Criteria:

  • Lack of fluency in English
  • Not female between the ages of 19-45
  • Not previously sexually active
  • Any previous deliveries, either vaginal or by c-section
  • Any sexual arousal disorder
  • Any genital pain or pelvic pain disorders
  • Any bowel or bladder syndromes (e.g. interstitial cystitis, irritable bowel disease, Chron's disease)
  • Any urinary incontinence or pelvic organ prolapse
  • Undergone medically induced menopause
  • Undergone total or partial hysterectomy
  • Undergone surgery for incontinence or prolapse
  • Using estrogen suppression medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01700361

Locations
Canada, British Columbia
Department of Gynaecology
Vancouver, British Columbia, Canada, V5Z 1M9
Sponsors and Collaborators
University of British Columbia
Investigators
Principal Investigator: Lori A. Brotto, PhD University of British Columbia
  More Information

Additional Information:
No publications provided

Responsible Party: University of British Columbia
ClinicalTrials.gov Identifier: NCT01700361     History of Changes
Other Study ID Numbers: H12-01852
Study First Received: August 27, 2012
Last Updated: June 3, 2013
Health Authority: Canada: Health Canada

Keywords provided by University of British Columbia:
sexual arousal
pelvic floor sEMG

ClinicalTrials.gov processed this record on July 22, 2014